Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - Phase I/II trial: Study protocol

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Combs, Stephanie E ^a   Heeger, Steffen ^c   Haselmann, Renate ^a   Edler, Lutz ^b   Debus, Jürgen ^a   Schulz Ertner, Daniela ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; TEMOZOLOMIDE;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEASIBILITY STUDY; GLIOBLASTOMA; HUMAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STANDARDIZATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 33746635527     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-133     Document Type: Article

References (53)

1. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
2. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5:1725-1731.
3. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003, 21:3276-3284.
4. Stupp R, Newlands E: New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol 2001, 28:19-23.
5. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
6. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
7. Stupp R, Dietrich PY, Ostermann KS, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
8. Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, Wannenmacher MM, Debus J: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005, 181:372-377.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
10. Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001, 19:32S-40S.
11. Wells A: EGF receptor. Int J Biochem Cell Biol 1999, 31:637-643.
12. Sedlacek HH: Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000, 59:435-476.
13. Hoi SU, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein. J Neurosurg 1995, 82:847-857.
14. Hoi SU, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 1995, 82:841-846.
15. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992, 66:373-385.
16. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M: Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994, 56:72-77.
17. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 1996, 85:634-641.
18. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD: Antisynthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990, 87:4207-4211.
19. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992, 89:2965-2969.
20. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995, 6:1251-1259.
21. Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003, 30:3-14.
22. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004, 22:2610-2616.
23. Baumann M, Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004, 72:257-266.
24. Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K, Lammering G, Amir C, Schmidt-Ullrich RK: The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001, 20:1388-1397.
25. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353:2012-2024.
26. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
27. Kim ES, Khuri FR, Herbst RS: Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001, 13:506-513.
28. Bonner JA, De Los SJ, Waksal HW, Needle MN, Trummel HQ, Raisch KP: Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002, 12:11-20.
29. Bonner JA, Harari PM, Giralt JL: Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol Abstract 2004, 5507:.
30. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
31. 2006 [http://www.klinikum.uni-heidelberg.de]. (Homepage)
32. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
33. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S: Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995, 13:1249-1254.
34. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D: Reirradiation of Recurrent WHO Grade III Astrocytomas Using Fractionated Stereotactic Radiotherapy (FSRT). Strahlenther Onkol 2005, 181:768-773.
35. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005, 23:8863-8869.
36. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D: Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 2005, 104:2168-2173.
37. Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D: Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 2005, 74:167-171.
38. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J: Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys 2005, 62:814-819.
39. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys 2005, 62:797-802.
40. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol 2005, 71:319-323.
41. Plathow C, Schulz-Ertner D, Thilman C, Zuna I, Lichy M, Weber MA, Schlemmer HP, Wannenmacher M, Debus J: Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2003, 57:996-1003.
42. Schulz-Ertner D, Nikoghosyan A, Didinger B, Debus J: Carbon ion radiation therapy for chordomas and low grade chondrosarcomas - current status of the clinical trials at GSI. Radiother Oncol 2004, 73(Suppl 2):S53-S56.
43. Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, Jakel O, Karger CP, Debus J: Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005, 104:338-344.
44. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Kraft G, Wannenmacher M, Debus J: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004, 58:631-640.
45. Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenmacher M, Debus J: Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 2002, 54:1114-1120.
46. Schulz-Ertner D, Debus J, Lohr F, Frank C, Hoss A, Wannenmacher M: Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors. Radiother Oncol 2000, 57:215-223.
47. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer 2005, 104:2457-2465.
48. Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J: Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys 2005, 62:814-819.
49. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys 2005, 62:797-802.
50. Munter MW, Thieke C, Nikoghosyan A, Nill S, Debus J: Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience. Lung Cancer 2005, 49(Suppl 1):S83-S86.
51. Munter MW, Nill S, Thilmann C, Hof H, Hoss A, Haring P, Partridge M, Manegold C, Wannenmacher M, Debus J: Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results. Strahlenther Onkol 2003, 179:535-541.
52. Munter MW, Thilmann C, Hof H, Didinger B, Rhein B, Nill S, Schlegel W, Wannenmacher M, Debus J: Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol 2003, 66:313-321.
53. Munter MW, Debus J, Hof H, Nill S, Haring P, Bortfeld T, Wannenmacher M: Inverse treatment planning and stereotactic intensity-modulated radiation therapy (IMRT) of the tumor and lymph node levels for nasopharyngeal carcinomas. Description of treatment technique, plan comparison, and case study. Strahlenther Onkol 2002, 178:517-523.